Tazemetostat in combination with lenalidomide and rituximab for R/R follicular lymphoma

(1:48)

Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors

(1:47)

Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma

(1:11)

Dr. Chi on Response to Tazemetostat in Children With INI1-Negative Tumors

(1:10)

Dr. Leonard on the FDA Approval of Tazemetostat in Follicular Lymphoma

(1:16)

Dr. Chi on Tazemetostat in Pediatric Patients With INI1-Negative Tumors

(58)

Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma

(1:8)

Tazemetostat for the treatment of R/R FL

(10:16)

Exploring the Tazemetostat Approval in R/R Follicular Lymphoma

(1:31)

Dr. Skarbnik on the Approval of Tazemetostat in Relapsed/Refractory Follicular Lymphoma

(57)

Dr. Burke on Tazemetostat’s Mechanism of Action in EZH2-Mutated Follicular Lymphoma

(1:35)

Accelerated Approval of Tazemetostat For Follicular Lymphoma

(3:55)

Mezigdomide, dexamethasone and tazemetostat in patients with multiple myeloma in the CA057-003 trial

(2:7)

Sarcoma Treatment with Targeted Therapies: Tazemetostat

(3:3)

Dr. Michael Dickinson: Tazemetostat in FL and DLBCL – ICML 2017

(4:55)

Update on ETCTN P10500, a Phase I study of tazemetostat plus belinostat for the treatment of R/R NHL

(4:5)

Tazemetostat and rituximab in r/r follicular lymphoma

(38)

John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma

(1:16)

Trial-in-progress: tazemetostat with rituximab for R/R follicular lymphoma

(1:31)

Tazemetostat for treatment of epitheloid sarcoma (New Drug 2020)

(3:32)